Alcohol Intake in Patients With Cardiomyopathy and Heart Failure: Consensus and Controversy.


Journal

Circulation. Heart failure
ISSN: 1941-3297
Titre abrégé: Circ Heart Fail
Pays: United States
ID NLM: 101479941

Informations de publication

Date de publication:
08 2022
Historique:
pubmed: 21 5 2022
medline: 19 8 2022
entrez: 20 5 2022
Statut: ppublish

Résumé

Alcohol is often cited to be a common cause of cardiomyopathy and heart failure. However, in most available population-based studies, a modest-to-moderate alcohol consumption has been associated with favorable effects on the cardiovascular system, including a lowered risk of heart failure, compared with no alcohol consumption. Available genetic epidemiological data have not supported a causal association between alcohol consumption and heart failure risk, suggesting that alcohol may not be a common cause of heart failure in the community. Data linking alcohol intake with cardiomyopathy risk are sparse, and the concept of alcoholic cardiomyopathy stems mainly from case series of selected patients with dilated cardiomyopathy, where a large proportion reported a history of excessive alcohol intake. This state-of-the-art paper addresses the current knowledge of the epidemiology of alcoholic cardiomyopathy and the role of alcohol intake in patients with non-alcohol-related heart failure. It also offers directions to future research in the area. The review questions the validity of current clinical teaching in the area. It is not well known how much alcohol is needed to cause disease, and the epidemiological pathways linking alcohol consumption to cardiomyopathy and heart failure are not well understood. Until more evidence becomes available, caution is warranted before labeling patients as having alcoholic cardiomyopathy due to a risk of neglecting other contributors, such as genetic causes of cardiomyopathy. In non-alcohol-related heart failure, it is unknown whether total abstinence is improving outcomes (compared with moderate drinking). Ideally, randomized clinical trials are needed to answer this question.

Identifiants

pubmed: 35593142
doi: 10.1161/CIRCHEARTFAILURE.121.009459
doi:

Substances chimiques

Ethanol 3K9958V90M

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e009459

Auteurs

Charlotte Andersson (C)

Department of Medicine, Section of Cardiovascular Medicine, Boston Medical Center, Boston University, MA (C.A.).

Morten Schou (M)

Department of Cardiology, Herlev and Gentofte Hospital (M.S.), University of Copenhagen, Denmark.

Finn Gustafsson (F)

The Heart Centre, Rigshospitalet (F.G.), University of Copenhagen, Denmark.

Christian Torp-Pedersen (C)

Department of Cardiology, Hillerød Hospital (C.T.-P.), University of Copenhagen, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH